KEEPSaKe-1 Trial in PsA - IL-23 Inhibition is Effective The KEEPSaKE-1 study in PsA has been published and shows that RIZ showed significant clinical improvements when given to active PsA patients who failed or were intolerant to ≥1 csDMARD. https://t.co/thYavd4dAR https://t.co/HnVtsrUgVB